Prostate cancer is a leading cause of cancer for men within the United States with estimates in 2020 of more than 191,000 new cases per year, and 30,000 deaths. The current gold standard for prostate cancer diagnosis – needle biopsy – often lacks a true reflection of the molecular profile of the tissue given sampling error and complex tumor heterogeneity. Further, the relative lack of PSA specificity for prostate cancer has led to overdiagnosis of clinically insignificant prostate cancer.
There is growing demand for diagnostic tools that provide prognostic information to identify the right patient to undergo biopsy at the right time, while avoid missing highgrade prostate cancers (HGPCa). Liquid biopsy is a noninvasive method that may improve early detection of highgrade prostate cancer and therefore inform patients’ treatment selection. The ExoDx™ Prostate Test, or “EPI” is a validated, noninvasive urine gene expression assay that provides actionable information that aids the prostate biopsy decision for men in the PSA ‘gray zone’ of 210ng/mL and is not dependent on clinical factors such as PSA, and other clinical risk factors.

Learn more at https://www.exosomedx.com/

Learning Objectives:
•Address practical challenges in prostate cancer risk assessment
•Review validation and economic studies demonstrating performance of the ExoDx Prostate Test in the “intended use” population
•Highlight clinical utility in a realworld urology practice setting with a focus on the physicianpatient shared decision making
•Evaluate performance of the ExoDx Prostate risk assessment test with standard of care parameters, such as PSA and widely used risk calculators

Featured Speaker:

Dr. Judd Moul joined the Duke faculty in mid2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center. He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. Dr. Moul served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology. He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.

Dr. Moul has performed more than 1800 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer. He has published over 625 medical and scientific manuscripts and book chapters and has lectured at national and international meetings as a prostate cancer authority. Dr. Moul served as the Editor for Prostate Cancer and Prostatic Disease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World. He is very committed to training residents and mentoring students and trainees.